source
- FDA proposes removing semaglutide, tirzepatide, liraglutide from 503B compounding listThe FDA has proposed removing the active ingredients of several popular GLP‑1 drugs from the 503B compounding list. The agency says there is no clinical need for large compounding facilities to pr…
- Democrats unveil plan to lower health care costs across the boardSenate Minority Leader Chuck Schumer presented a health policy outline that calls for reducing patient costs for all services and treatments. The proposal emphasizes lowering expenses universally,…